AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32658013 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue CMV PCR positivity
Number of subjects: 76
Study 32658013 — intervention group
Group type: COMPARATOR
Intervention: Histopathological examinations (HE/IHC)
Number of subjects: 76
Study 32658013 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood CMV viral load (BVL)
Number of subjects: 76
Study 32658013 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue viral load (TVL)
Number of subjects: 76
Study 32658013 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue CMV DNA
Number of subjects: 76
Study 35241023 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic acid (TXA)
Number of subjects: 0
Study 35241023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32521015 — intervention group
Group type: EXPERIMENTAL
Intervention: diacerein 50 mg once daily for 1 month and twice daily thereafter (n=140)
Number of subjects: 380
Study 32521015 — intervention group
Group type: COMPARATOR
Intervention: celecoxib 200 mg once daily (n=148)
Number of subjects: 380
Study 32521015 — intervention group
Group type: EXPERIMENTAL
Intervention: diacerein
Number of subjects: 380
Study 32521015 — intervention group
Group type: COMPARATOR
Intervention: celecoxib
Number of subjects: 380
Study 36219237 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI_score based on histogram features of multi b‐value DWI functional parameters
Number of subjects: 161
Study 36219237 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model combining DWI_score, TNM-stage, mesorectal fascia (MRF), and extramural venous invasion (EMVI)
Number of subjects: 161
Study 36219237 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean value of functional parameters from multi b‐value DWI
Number of subjects: 161
Study 32299481 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-made combined elastic compression device
Number of subjects: 59
Study 32299481 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 59
Study 34489860 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 130
Study 34489860 — intervention group
Group type: COMPARATOR
Intervention: Metformin only (Control)
Number of subjects: 130
Study 37462593 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic complete revascularization (ACR) in INV group
Number of subjects: 4824
Study 37462593 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional complete revascularization (FCR) in INV group
Number of subjects: 4824
Study 37462593 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving complete revascularization (CR) in all INV patients
Number of subjects: 4824
Study 37462593 — intervention group
Group type: EXPERIMENTAL
Intervention: INV management strategy
Number of subjects: 4824
Study 37462593 — intervention group
Group type: COMPARATOR
Intervention: CON management strategy
Number of subjects: 4824
Study 32640842 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra rapid lispro (URLi)
Number of subjects: 49
Study 32640842 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro (Humalog®)
Number of subjects: 49
Study 32978185 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical care telehealth program (daily telemedical rounds at ICU)
Number of subjects: 1431
Study 32978185 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 1431
Study 32978185 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical care telehealth program
Number of subjects: 1431
Study 36714789 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Physical Activity (EPA) exercise intervention group
Number of subjects: 23
Study 36714789 — intervention group
Group type: COMPARATOR
Intervention: Usual Physical Activity (UPA) group
Number of subjects: 23
Study 36714789 — intervention group
Group type: COMPARATOR
Intervention: Comparison between UPA and EPA groups
Number of subjects: 23
Study 32495860 — intervention group
Group type: EXPERIMENTAL
Intervention: ERBB2 shRNA group
Number of subjects: 240
Study 32495860 — intervention group
Group type: EXPERIMENTAL
Intervention: ERBB2 overexpression group
Number of subjects: 240
Study 32495860 — intervention group
Group type: COMPARATOR
Intervention: Blank group
Number of subjects: 240
Study 32495860 — intervention group
Group type: COMPARATOR
Intervention: Negative control (NC) group
Number of subjects: 240
Study 36061844 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle ACLR with lateral release (group 3)
Number of subjects: 100
Study 36061844 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle ACLR (group 1)
Number of subjects: 100
Study 36061844 — intervention group
Group type: COMPARATOR
Intervention: Double-bundle ACLR (group 2)
Number of subjects: 100
Study 33637547 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 60
Study 33637547 — intervention group
Group type: COMPARATOR
Intervention: Sugammadex
Number of subjects: 60
Study 33637547 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine and Sugammadex
Number of subjects: 60
Study 33396458 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil (FO) supplementation
Number of subjects: 143
Study 33396458 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (5-MTHF) supplementation
Number of subjects: 143
Study 33396458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 33396458 — intervention group
Group type: EXPERIMENTAL
Intervention: FO + 5-MTHF supplementation
Number of subjects: 143
Study 33396458 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher AA/DHA ratio at delivery
Number of subjects: 143
Study 33396458 — intervention group
Group type: EXPERIMENTAL
Intervention: FADS1 rs174556 heterozygotes
Number of subjects: 143
Study 33396458 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal tHcy levels at delivery
Number of subjects: 143
Study 34931908 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support group for 10 weeks
Number of subjects: 42
Study 34931908 — intervention group
Group type: COMPARATOR
Intervention: General health reading material for 10 weeks (Control)
Number of subjects: 42
Study 34702595 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulative heartbeat nest with a heart beating device for 15 minutes
Number of subjects: 52
Study 34702595 — intervention group
Group type: COMPARATOR
Intervention: Control group observed in the nest without the device for 15 minutes
Number of subjects: 52
Study 36482468 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-Centre
Number of subjects: 129
Study 36482468 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-Home
Number of subjects: 129
Study 36482468 — intervention group
Group type: COMPARATOR
Intervention: AR-All
Number of subjects: 129
Study 34552706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary electrocardiogram (IEGM) guided diagnosis under data mining algorithms
Number of subjects: 100
Study 34552706 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrocardiogram (EGM) diagnosis
Number of subjects: 100
Study 32194219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 164
Study 32194219 — intervention group
Group type: COMPARATOR
Intervention: Non-sitagliptin
Number of subjects: 164
Study 35401769 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT + RT
Number of subjects: 76
Study 35401769 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT + RT
Number of subjects: 76
Study 35401769 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study 33010241 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Number of subjects: 613
Study 33010241 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 400 mg
Number of subjects: 613
Study 34294398 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 781
Study 34294398 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Aortic Valve Replacement (SAVR)
Number of subjects: 781
Study 34294398 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 781
Study 32932898 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + ozonated olive oil mouthwash
Number of subjects: 96
Study 32932898 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 96
Study 34118635 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medication (long-term use)
Number of subjects: 120
Study 34118635 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants plus lithium (long-term use)
Number of subjects: 120
Study 34118635 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics (long-term use)
Number of subjects: 120
Study 34118635 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychological therapy (ASSIP) added to medication
Number of subjects: 120
Study 34118635 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 120
Study 32027542 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated-water exercise therapy (HWET) for 12 weeks
Number of subjects: 53
Study 32027542 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercise therapy (LBET) for 12 weeks
Number of subjects: 53
Study 32027542 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HWET and LBET
Number of subjects: 53
Study 32027542 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated-water exercise therapy (HWET)
Number of subjects: 53
Study 32027542 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercise therapy (LBET)
Number of subjects: 53
Study 32956264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud pack with menthol and Arnica montana (MUD)
Number of subjects: 10
Study 32956264 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study 33862001 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg tablets twice per day for up to 2 years)
Number of subjects: 391
Study 33862001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 33862001 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 391
Study 35502234 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal drugs for cancer therapy
Number of subjects: 74
Study 35502234 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional trials
Number of subjects: 74
Study 35502234 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 3 trials
Number of subjects: 74
Study 35502234 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 1 trials
Number of subjects: 74
Study 35502234 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 trials
Number of subjects: 74
Study 32033103 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg/b.m.
Number of subjects: 12
Study 32033103 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg/kg/b.m.
Number of subjects: 12
Study 32033103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 32033103 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 and 6 mg/kg/b.m.)
Number of subjects: 12
Study 34965954 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 0
Study 34965954 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 0
Study 34965954 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX/bevacizumab
Number of subjects: 0
Study 34965954 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX/cetuximab
Number of subjects: 0
Study 33434107 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte count 0.60 to <0.95 × 10^9 cells/L
Number of subjects: 2067
Study 33434107 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte count ≥0.95 × 10^9 cells/L
Number of subjects: 2067
Study 33434107 — intervention group
Group type: COMPARATOR
Intervention: Monocyte count <0.60 × 10^9 cells/L
Number of subjects: 2067
Study 32447638 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB‐EMS)
Number of subjects: 20
Study 32447638 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 20
Study 35557386 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal exercise maintenance (EX)
Number of subjects: 19
Study 35557386 — intervention group
Group type: COMPARATOR
Intervention: Removal of exercise (NOEX)
Number of subjects: 19
Study 34795281 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) every 4 weeks
Number of subjects: 326
Study 34795281 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP) every 12 weeks
Number of subjects: 326
Study 34795281 — intervention group
Group type: EXPERIMENTAL
Intervention: PPQ level of 15.4 ng/mL
Number of subjects: 326
Study 34795281 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition
Number of subjects: 326
Study 34795281 — intervention group
Group type: EXPERIMENTAL
Intervention: DP every 4 weeks
Number of subjects: 326
Study 35726182 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% DMSO
Number of subjects: 24
Study 35726182 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3M EDC
Number of subjects: 24
Study 35726182 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CHX
Number of subjects: 24
Study 35726182 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 24
Study 34579064 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill protein hydrolysate
Number of subjects: 10
Study 34579064 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Number of subjects: 10
Study 34579064 — intervention group
Group type: COMPARATOR
Intervention: Soy protein isolate
Number of subjects: 10
Study 32142961 — intervention group
Group type: EXPERIMENTAL
Intervention: myAirCoach support for 3 to 6 months (study 1)
Number of subjects: 42
Study 32142961 — intervention group
Group type: EXPERIMENTAL
Intervention: myAirCoach system for 3 months (study 2)
Number of subjects: 42
Study 35545388 — intervention group
Group type: EXPERIMENTAL
Intervention: Development and Well‐Being Assessment SDA tool as an adjunct to usual clinical care
Number of subjects: 1210
Study 35545388 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 1210
Study 33594151 — intervention group
Group type: EXPERIMENTAL
Intervention: XP-endo Shaper files
Number of subjects: 45
Study 33594151 — intervention group
Group type: EXPERIMENTAL
Intervention: Kedo-S files
Number of subjects: 45
Study 33594151 — intervention group
Group type: COMPARATOR
Intervention: Hand K-files
Number of subjects: 45
Study 32255580 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 6
Study 32255580 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 6
Study 32255580 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid injections
Number of subjects: 6
Study 34260693 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic eradication therapy (EET)
Number of subjects: 269
Study 34260693 — intervention group
Group type: COMPARATOR
Intervention: Esophagectomy
Number of subjects: 269
Study 34645661 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialised outpatient treatment in CAG Bipolar
Number of subjects: 1000
Study 34645661 — intervention group
Group type: COMPARATOR
Intervention: Generalised community‐based outpatient treatment
Number of subjects: 1000
Study 32162075 — intervention group
Group type: EXPERIMENTAL
Intervention: GAMBOT intervention delivered through a messaging app for 28 days
Number of subjects: 197
Study 32162075 — intervention group
Group type: COMPARATOR
Intervention: Assessments only (control group) for 28 days
Number of subjects: 197
Study 35306405 — intervention group
Group type: EXPERIMENTAL
Intervention: daridorexant 50 mg
Number of subjects: 28
Study 35444614 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and surgery
Number of subjects: 323
Study 35444614 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 323
Study 32768608 — intervention group
Group type: EXPERIMENTAL
Intervention: A3 test (triple adenylate nucleotides test)
Number of subjects: 400
Study 32768608 — intervention group
Group type: COMPARATOR
Intervention: ATP test (adenosine triphosphate test)
Number of subjects: 400
Study 34218214 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 42
Study 34218214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 33208330 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic treatment for lexical retrieval deficits in the optimal language determined by the BiLex model.
Number of subjects: 48
Study 33208330 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving treatment in the language opposite to the model's recommendation.
Number of subjects: 48
Study 35587704 — intervention group
Group type: EXPERIMENTAL
Intervention: DLw (deadlifts with lifting straps)
Number of subjects: 16
Study 35587704 — intervention group
Group type: EXPERIMENTAL
Intervention: DLn (deadlifts without lifting straps)
Number of subjects: 16
Study 35587704 — intervention group
Group type: COMPARATOR
Intervention: DLwn (deadlifts with lifting straps against 80% of DLn 1RM)
Number of subjects: 16
Study 35587704 — intervention group
Group type: COMPARATOR
Intervention: DLnn (deadlifts without lifting straps against 80% of DLn 1RM)
Number of subjects: 16
Study 35587704 — intervention group
Group type: COMPARATOR
Intervention: DLww (deadlifts with lifting straps against 80% of DLw 1RM)
Number of subjects: 16
Study 35587704 — intervention group
Group type: COMPARATOR
Intervention: First repetition as reference
Number of subjects: 16
Study 34360293 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet + unsupervised exercise training
Number of subjects: 61
Study 34360293 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet
Number of subjects: 61
Study 36377146 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacs left open during herniotomy (experimental group)
Number of subjects: 151
Study 36377146 — intervention group
Group type: COMPARATOR
Intervention: High ligation of hernia sac (control group)
Number of subjects: 151
Study 34182611 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8154 inhaled doses (0.1–7.7 mg)
Number of subjects: 78
Study 34182611 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8154 IV infusion (0.15 mg)
Number of subjects: 78
Study 34182611 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8154 inhaled doses (0.6, 1.8, and 3.1 mg) with once-daily dosing on Days 4–12
Number of subjects: 78
Study 34182611 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8154 (all forms)
Number of subjects: 78
Study 34182611 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8154 inhaled route
Number of subjects: 78
Study 34182611 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8154
Number of subjects: 78
Study 34976111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided laparoscopic technology for postoperative analgesia
Number of subjects: 0
Study 34976111 — intervention group
Group type: COMPARATOR
Intervention: Traditional postoperative analgesia methods
Number of subjects: 0
Study 37173691 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility-based care (FBC) plus community-based rehabilitation (CBR)
Number of subjects: 264
Study 37173691 — intervention group
Group type: COMPARATOR
Intervention: Facility-based care (FBC) alone
Number of subjects: 264
Study 33587007 — intervention group
Group type: EXPERIMENTAL
Intervention: Escape room before simulation
Number of subjects: 233
Study 33587007 — intervention group
Group type: COMPARATOR
Intervention: Escape room after simulation
Number of subjects: 233
Study 34001174 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (1 to 2 units of 200 to 250 ml) along with local standard treatment
Number of subjects: 100
Study 34001174 — intervention group
Group type: COMPARATOR
Intervention: Local standard treatment alone
Number of subjects: 100
Study 33120838 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique 'Scotty dog' approach (OS)
Number of subjects: 70
Study 33120838 — intervention group
Group type: COMPARATOR
Intervention: Anteroposterior approach (AP)
Number of subjects: 70
Study 33120838 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 36196598 — intervention group
Group type: EXPERIMENTAL
Intervention: T1D with microvascular complications group
Number of subjects: 84
Study 33905041 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (0.25 g)
Number of subjects: 22
Study 33905041 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (20.0 g) with vitamin C (0.25 g)
Number of subjects: 22
Study 33905041 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20.0 g of white rice flour) with vitamin C (0.25 g)
Number of subjects: 22
Study 32728763 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast augmentation with various implant volumes and textures
Number of subjects: 74
Study 32728763 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast projection measurement
Number of subjects: 74
Study 32728763 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements stability
Number of subjects: 74
Study 35831692 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on the log odds of the negative lymph node/T stage ratio (LONT)
Number of subjects: 3895
Study 35831692 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram risk score
Number of subjects: 3895
Study 35831692 — intervention group
Group type: EXPERIMENTAL
Intervention: Low LONT
Number of subjects: 3895
Study 33734046 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic respiratory muscle training
Number of subjects: 53
Study 33734046 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined respiratory muscle training
Number of subjects: 53
Study 33734046 — intervention group
Group type: EXPERIMENTAL
Intervention: Static respiratory muscle training
Number of subjects: 53
Study 33734046 — intervention group
Group type: COMPARATOR
Intervention: Breathing without applied resistance (Control)
Number of subjects: 53
Study 33887380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi intervention (2 classes of 60 min duration per week for 10 weeks)
Number of subjects: 30
Study 33887380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi intervention
Number of subjects: 30
Study 32548849 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium alginate (Gaviscon Advance)
Number of subjects: 30